What is essential is that MIP-3α/CCL20 primarily attracts Th17 cells and is associated with neutrophilic inflammation and severe asthma phenotypes, suggesting that the efficacy of these three biologics may be partially influenced by the inhibition of Th17-associated inflammatory pathways. This evidence concerns the gene CCL20 and asthma.